Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression
NCT06480500Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Jan 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in treatment-resistant depression (TRD), Suicidal Behavior (SB), sponsored by University Health Network. Started Jan 2024; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)Suicidal Behavior (SB)
Beyond the preview
Go deeper on NCT06480500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480500.